ClinicalTrials.gg

Program

mtbvac

Its studies are mostly in Tuberculosis, led by 2 companies.

Furthest: phase 3, since Jun 21, 20214 company-led studies, 2 open or runningNext primary completion: Feb 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biofabri, S.L31 open or runningphase 3since Jun 21, 2021Mar 15, 2016Feb 2029phase 3 · NCT04975178
Bharat Biotech International11 open or runningphase 2since May 14, 2025May 14, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 15, 2016First study: phase 2 study in TuberculosisNew to Biofabri, S.LBiofabri, S.L · NCT02729571 · 54 enrolled · South Africa
  2. Feb 16, 2018Phase 2 study in TuberculosisBiofabri, S.L · NCT03536117 · 99 enrolled · South Africa
  3. Jun 21, 2021Phase 3 study in TuberculosisBiofabri, S.L · NCT04975178 · 7,120 planned · South Africa
  4. May 14, 2025Bharat Biotech International's first study: phase 2 study in TuberculosisNew to Bharat Biotech InternationalBharat Biotech International · NCT06997367 · 164 enrolled · India

Ahead

  1. Feb 2029Primary completion: phase 3 study in TuberculosisBiofabri, S.L · NCT04975178

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06997367Tuberculosis · India2Active, not recruitingBharat Biotech InternationalSep 1, 2025164
NCT04975178Tuberculosis · South Africa3RecruitingBiofabri, S.LFeb 20297,120
NCT03536117Tuberculosis · South Africa2CompletedBiofabri, S.LMay 17, 202299
NCT02729571Tuberculosis · South Africa2CompletedBiofabri, S.LSep 201654

How it is read

Names in the registry

  • “MTBVAC”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.